智通财经网·2025-08-20 13:21Core Viewpoint - Haohai Biology (688366.SH) announced that Carl Zeiss intends to acquire 100% of Hengtai Optical through a share conversion, resulting in a change of control over Hengtai Optical [1] Group 1: Agreement and Termination - Haohai Holdings and Hengtai Optical's existing major shareholders and stakeholders signed a "Termination Cooperation Agreement" [1] - All parties agreed to ensure that Hengtai Optical, Haohai Holdings, and Hengtai Vision sign a "Termination Confirmation Letter" after the "Termination Cooperation Agreement" is signed [1] - The exclusive distribution agreement will be terminated one day before the share conversion benchmark date between Hengtai Optical and Carl Zeiss, with Hengtai Optical's major shareholders and stakeholders paying a termination compensation of 80 million yuan to Haohai Holdings [1] Group 2: Share Transfer and Future Structure - Before the formal termination of the exclusive distribution agreement, all parties must continue to perform related agreements normally [1] - After the completion of relevant handover work, Hengtai Vision's minority shareholder, Jinhengtai (Xiamen) Trading Co., Ltd., will sign a "Share Transfer Agreement" with Haohai Development [1] - The share transfer price will be calculated based on Hengtai Vision's book net assets as of September 30, 2025, with Jinhengtai (Xiamen) transferring its entire 45% stake in Hengtai Vision to Haohai Development, making Hengtai Vision a wholly-owned subsidiary of Haohai Development and continuing to be included in the company's consolidated financial statements [1]